Skip to content
Portage BioTech, LLC.
Portage BioTech, LLC.Portage BioTech, LLC.
  • about us
    • overview
    • leadership
  • our portfolio
    • PORT-2 & PORT-3 – iNKT agonists
    • PORT-1 – Intratumoral Amphiphilic Formulations
    • PORT-4 – Nanolipogel Formulations
    • PORT-5 – STING Agonist with VLP Delivery
  • news
  • investors / media
    • investor home
    • stock information
    • company information and policies
    • financial and regulatory reports
    • shareholder circular
    • details of key advisors
    • press releases
  • contact
  • about us
    • overview
    • leadership
  • our portfolio
    • PORT-2 & PORT-3 – iNKT agonists
    • PORT-1 – Intratumoral Amphiphilic Formulations
    • PORT-4 – Nanolipogel Formulations
    • PORT-5 – STING Agonist with VLP Delivery
  • news
  • investors / media
    • investor home
    • stock information
    • company information and policies
    • financial and regulatory reports
    • shareholder circular
    • details of key advisors
    • press releases
  • contact

Daily Archives: February 11, 2021

PORTAGE BIOTECH PROVIDES RESEARCH AND DEVELOPMENT UPDATE AND ANNOUNCES NASDAQ LISTING APPROVAL

Press ReleaseBy Portage Biotech, IncFebruary 11, 2021
...
Copyright © All rights reserved Portage Biotech, Inc

terms of use   privacy policy   disclaimer

Go to Top